{"id":390872,"date":"2017-10-30T00:00:00","date_gmt":"2017-10-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0008-2017-biopharma-biosimilars-current-treatment-nephrology-us-eu-2017\/"},"modified":"2026-03-31T10:49:41","modified_gmt":"2026-03-31T10:49:41","slug":"biosbi0008-2017-biopharma-biosimilars-current-treatment-nephrology-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0008-2017-biopharma-biosimilars-current-treatment-nephrology-us-eu-2017\/","title":{"rendered":"Biosimilars | Current Treatment | Nephrology | US\/EU | 2017"},"content":{"rendered":"<p>Although\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA\u00a0<\/abbr>biosimilars\u00a0entered\u00a0the\u00a0European\u00a0market\u00a0a\u00a0decade\u00a0ago,\u00a0their\u00a0uptake\u00a0varies\u00a0from\u00a0country\u00a0to\u00a0country,\u00a0as\u00a0well\u00a0as\u00a0by\u00a0drug\u00a0and\u00a0manufacturer.\u00a0While\u00a0European\u00a0nephrologists\u00a0have\u00a0been\u00a0able\u00a0to\u00a0prescribe\u00a0biosimilar\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>s\u00a0to\u00a0their\u00a0<abbr title=\"chronic kidney disease\">CKD<\/abbr>\u00a0patients\u00a0for\u00a0a\u00a0number\u00a0of\u00a0years,\u00a0no\u00a0biosimilar\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>s\u00a0are\u00a0as\u00a0yet\u00a0available\u00a0to\u00a0U.S.\u00a0nephrologists.\u00a0With\u00a0epoetin\u00a0alfa\u00a0biosimila\u00a0nearing\u00a0launch\u00a0in\u00a0the\u00a0United\u00a0States,\u00a0and\u00a0with\u00a0new\u00a0biosimilars\u00a0expected\u00a0to\u00a0enter\u00a0all\u00a0markets\u00a0in\u00a0the\u00a0near-term\u00a0future,\u00a0it\u00a0is\u00a0vital\u00a0to\u00a0understand\u00a0why\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>\u00a0biosimilar\u00a0uptake\u00a0varies\u00a0in\u00a0Europe,\u00a0and\u00a0how\u00a0it\u00a0might\u00a0impact\u00a0upcoming\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>\u00a0biosimilar\u00a0launches\u00a0in\u00a0the\u00a0United\u00a0States\u00a0and\u00a0Europe.\u00a0We\u00a0surveyed\u00a0nephrologists\u00a0from\u00a0France,\u00a0Germany,\u00a0and\u00a0the\u00a0United\u00a0States\u00a0about\u00a0their\u00a0experience,\u00a0familiarity\u00a0with,\u00a0and\u00a0attitudes\u00a0toward\u00a0current\u00a0biosimilars;\u00a0the\u00a0drivers\u00a0and\u00a0barriers\u00a0to\u00a0biosimilars\u2019\u00a0uptake;\u00a0and\u00a0their\u00a0expectations\u00a0for\u00a0novel\u00a0biosimilars.<\/p>\n","protected":false},"template":"","class_list":["post-390872","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390872\/revisions"}],"predecessor-version":[{"id":393996,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390872\/revisions\/393996"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}